IJMS | Free Full-Text | Intravitreal Injection of Ranibizumab and CTGF shRNA Improves Retinal Gene Expression and Microvessel Ultrastructure in a Rodent Model of Diabetes
Effectiveness of Continued Ranibizumab Therapy in Neovascular Age-Related Macular Degeneration versus Switch to Aflibercept: Real World Evidence - Ophthalmology Retina
Intraocular pharmacokinetics of intravitreal vascular endothelial growth factor-Trap in a rabbit model | Eye
Full article: Treatment of age-related macular degeneration: focus on ranibizumab
A Peek into the Diabetic Retinopathy Pipeline
Efficacy of ranibizumab and LAVA2 in the rabbit retinal vascular... | Download Scientific Diagram
A novel strategy for efficient expression of an antibody fragment in Escherichia coli: ranibizumab as a case study - Priyanka - 2022 - Journal of Chemical Technology & Biotechnology - Wiley Online Library
Evaluation of the Structural, Physicochemical, and Biological Characteristics of SB11, as Lucentis® (Ranibizumab) Biosimilar | SpringerLink
12) Patent Application Publication (10) Pub. No.: US 2016/0289314 A1
Cancers | Free Full-Text | Uptake of Ranibizumab but Not Bevacizumab into Uveal Melanoma Cells Correlates with a Sustained Decline in VEGF-A Levels and Metastatic Activities
Ranibizumab in diabetic macular edema
Emerging Treatments for Neovascular AMD - Retina Today
Antiangiogenic therapy for ocular diseases: Current status and challenges - Chen - 2023 - MedComm – Future Medicine - Wiley Online Library
Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab | Eye
Ranibizumab biosimilar/polyethyleneglycol-conjugated gold nanoparticles as a novel drug delivery platform for age-related macular degeneration - ScienceDirect
Ranibizumab Biosimilar, Research Grade, VEGF mAb - Ushelf
RU2646098C2 - New method of cloning, expression and purification for preparation of ranibizumab - Google Patents
_[Ranibizumab_Biosimilar_1].png "JAN: Japanese Accepted Names for Pharmaceuticals")
JAN: Japanese Accepted Names for Pharmaceuticals
A novel strategy for efficient expression of an antibody fragment in Escherichia coli: ranibizumab as a case study - Priyanka - 2022 - Journal of Chemical Technology & Biotechnology - Wiley Online Library
Schematic structures of ranibizumab (A), bevacizumab (B), and... | Download Scientific Diagram
Avastin and Lucentis: Two Sides of the Same Coin?
IMGt Protein displays of the VH and V-KAPPA domains of the bevacizumab... | Download Scientific Diagram
Coherus to Launch CIMERLI™ (ranibizumab-eqrn) in the United States on October 3, 2022
